<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029728</url>
  </required_header>
  <id_info>
    <org_study_id>BHAE 06-2018</org_study_id>
    <nct_id>NCT03029728</nct_id>
  </id_info>
  <brief_title>Biomarker for Hereditary AngioEdema Disease</brief_title>
  <acronym>BioHAE</acronym>
  <official_title>Biomarker for Hereditary AngioEdema Disease: An International, Multicenter, Longitudinal Monitoring Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal monitoring study to identify,&#xD;
      validate and/or monitor Mass Spectrometry (MS)-based biomarker/s for Hereditary Angioedeme&#xD;
      (HAE) disease and to test the clinical robustness, specificity, and predictive value of&#xD;
      theese biomarker/s&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hereditary Angioedema (HAE) is a rare autosomal dominant genetic disorder, characterized by&#xD;
      recurrent episodes of angioedema of the face, larynx, lips, abdomen, and extremities.The most&#xD;
      common types of HAE develop as result of mutations in the SERPING1 gene that encodes the C1&#xD;
      inhibitor (C1-INH), a protease involved in limiting bradykinin production. Excessive&#xD;
      bradykinin due to low levels of C1-INH (HAE type 1) or dysfunctional C1-INH (HAE type 2)&#xD;
      leads to capillary leakage and angioedema formation. The third type of HAE is not associated&#xD;
      with a C1-INH deficiency, develops as a result of mutations in the Factor 12 gene (FXII) and&#xD;
      affects almost exclusively women. Rare cases of HAE have also been described resulting from&#xD;
      mutations in Plasminogen (PLG), Angiopoetin 1 (ANGPT1), and Kininogen 1 (KNG1).&#xD;
&#xD;
      The characteristic symptom of hereditary angioedema is recurrent episodes of swelling due to&#xD;
      the accumulation of excessive body fluid. The most commonly affected areas of the body&#xD;
      include the hands, feet, eyelids, lips, genitals, larynx and gastrointestinal tract. The most&#xD;
      serious complication of HAE is laryngeal edema that can become life threatening; but it is a&#xD;
      relatively rare event.&#xD;
&#xD;
      The diagnosis of hereditary angioedema is made by a thorough clinical evaluation, a detailed&#xD;
      patient history, and blood tests.Clinical diagnosis is complicated because HAE is highly&#xD;
      variable in the clinical phenotype and the majority of the physicians believe that they never&#xD;
      seen a patient with that disorder. Laboratory diagnosis involves measurement of the C1-INH&#xD;
      function, C1-INH and C4 levels. Both C1-INH protein level and function is low in HAE-1&#xD;
      patients, whereas in HAE-2 individuals the C1-INH concentrations is optimal or even elevated,&#xD;
      however C1-INH function is impaired. Generally, C4 levels are low in both HAE-1/2 patients.&#xD;
&#xD;
      CENTOGENE utilizes Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry&#xD;
      (LC-MRM-MS) method to identify potential disease-specific biomarkers for HAE. Such&#xD;
      biomarker/s may support the early diagnosis and treatment monitoring and personalization in&#xD;
      the future.&#xD;
&#xD;
      Therefore, it is the goal of this study is to identify new biomarkers for HAE, validate the&#xD;
      identified biomarkers, and monitor these biomarkers longitudinally to determine their&#xD;
      clinical robustness, specificity, and predictive value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification, validation and/or monitoring of mass spectrometry (MS)-based biomarkers of Hereditary Angioedema (HAE) patients</measure>
    <time_frame>36 months</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the clinical robustness, specificity, and predictive value of the biomarker(s)</measure>
    <time_frame>36 months</time_frame>
    <description>Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>C1 Esterase Inhibitor Deficiency</condition>
  <condition>Angio Edema</condition>
  <condition>C4 Deficiency</condition>
  <condition>HAE</condition>
  <condition>Hereditary Angioedema</condition>
  <condition>Hereditary Angioedema Type II</condition>
  <condition>Hereditary Angioedema Type III</condition>
  <condition>Hereditary Angioedema Type I</condition>
  <arm_group>
    <arm_group_label>Participants with Hereditary Angioedema</arm_group_label>
    <description>Participants diagnosed with Hereditary Angioedema disease aged between 2 months and 60 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants diagnosed with Hereditary Angioedema (HAE) disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Informed consent is obtained from the participant or participant's parent/legal&#xD;
             guardian&#xD;
&#xD;
          -  The participant is aged between 2 months and 60 years&#xD;
&#xD;
          -  The diagnosis of Hereditary Angioedema is confirmed by CENTOGENE&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Participant is younger than 2 months or older than 60 years&#xD;
&#xD;
          -  The diagnosis of Hereditary Angioedema disease is not confirmed by CENTOGENE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CENTOGENE GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Selen Zülbahar, PhD</last_name>
    <phone>+49 (0)38180113431</phone>
    <email>Selen.Zuelbahar@centogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arabkir JMC-ICAH</name>
      <address>
        <city>Yerevan</city>
        <zip>0014</zip>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astghik Baghdasaryan, MD</last_name>
      <phone>+374 (0)10238526</phone>
      <phone_ext>2111 or 1004</phone_ext>
      <email>astghikbag@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Astghik Baghdasaryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center of Allergy and Immunology</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maia Gotua, MD</last_name>
      <phone>+995 (0)322520533</phone>
      <email>maia.gotua@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maia Gotua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Genetics, Amrita Institute of Medical Sciences &amp; Research Centre</name>
      <address>
        <city>Kerola</city>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <phone>+91 484 2851234</phone>
      <email>sheelanampoothiri@aims.amrita.edu</email>
    </contact>
    <investigator>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica San Pablo de Surco</name>
      <address>
        <city>Lima</city>
        <zip>1030</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Calderón Llosa, MD</last_name>
      <phone>+51 (0)984393379</phone>
      <email>oscarcalderonll@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oscar Calderón Llosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Krakau</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grzegorz Porebski, MD</last_name>
      <phone>+48 (0)124231123</phone>
      <email>g.porebski@uj.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Grzegorz Porebski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrul Clinic Mediquest</name>
      <address>
        <city>Târgu-Mureş</city>
        <zip>547530</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noemi Bara, MD</last_name>
      <phone>+40 (0)723395598</phone>
      <email>noemi.bara@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Noemi Bara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sakarya University Research and Training Hospital</name>
      <address>
        <city>Sakarya</city>
        <zip>54100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Öner Özdemir, MD</last_name>
      <phone>+90 (0)2642552110</phone>
      <phone_ext>1929</phone_ext>
      <email>ozdemir_oner@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Öner Özdemir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Georgia</country>
    <country>India</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://centogene.com</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Hereditary Angioedema Type I</keyword>
  <keyword>Hereditary Angioedema Type II</keyword>
  <keyword>Hereditary Angioedema Type III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Hereditary Angioedema Types I and II</mesh_term>
    <mesh_term>Hereditary Angioedema Type III</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

